Elicio Therapeutics (ELTX) TD Cowen 46th Annual Health Care Conference summary

Technology and platform overview

• Developing lymph node-targeted immunotherapies using the AMP platform, originally from MIT, to enhance immune cell activation against cancer.

• AMP platform chemically modifies immunotherapy payloads for efficient lymph node delivery via albumin binding, improving T cell responses.

• Platform supports a range of payloads (peptides, small molecules, nucleic acids) and is designed for off-the-shelf, scalable manufacturing.

• Mechanism enables robust T cell expansion and antigen spreading, addressing challenges of traditional peptide immunotherapies.

Lead program and clinical development

• Lead candidate ELI-002 targets mutated KRAS in GI cancers, especially pancreas and colorectal, with off-the-shelf formulation.

• Phase I trials showed strong T cell responses, median relapse-free survival of 16.33 months, and median OS up to 28.94 months in MRD-positive pancreas cancer.

• T cell response strength correlated with reduced relapse and death risk; antigen spreading observed, indicating personalized immune effects.

• Phase I and II studies confirmed safety, tolerability, and optimal dosing, with no DLTs or SAEs.

Phase II trial design and interim results

• Phase II focuses on pancreas cancer, enrolling 144 patients (KRAS-mutant, MRD+ or MRD-) in a 2:1 randomization against observation.

• Primary endpoint is disease-free survival; crossover allowed for observation arm after endpoint.

• Interim analysis confirmed safety and preliminary efficacy, with final analysis projected for H1 2026.

• T cell response rate in Phase II was 99%, with median 44-fold increase; 80% exceeded the clinical benefit threshold from Phase I.

• No significant HLA association found, supporting broad patient applicability.